Recovery of metabolic impairment of patients who cleared HCV infections after direct-acting antiviral therapy

Hepatitis C virus (HCV) is a single strained RNA virus identified as the causative agent of chronic hepatitis C (CHC) on April 1989. It is estimated that about 71 million individuals around the world are chronically infected with HCV. CHC is a major public health issue and it is associated with degenerative liver process dominated by necro-inflammatory damage leading to fibrosis, progressive decay of liver function, hepatocellular carcinoma (HCC), and, eventually, the death [1]. In many geographical settings HCV associated end-stage liver disease is the main reason of liver transplant [2].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Review Source Type: research